- $771.42m
- $1.01bn
- $38.47m
NASDAQ RESUMED AT 11:54 AM
Sleep apnea pill developer Apnimed rises in debut after upsized $192 mln IPO
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:49 AM
NASDAQ RESUMED AT 11:45 AM
Sleep apnea pill developer Apnimed poised to jump in debut after upsized IPO
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
Brief: Apnimed Announces Pricing Of Upsized Initial Public Offering
Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO